Fig. 7: Tumoral CCT6A levels as a prognostic indicator for anti-CD47 antibody immunotherapy in PDAC. | Cell Death & Disease

Fig. 7: Tumoral CCT6A levels as a prognostic indicator for anti-CD47 antibody immunotherapy in PDAC.

From: Tumor-derived exosomal CCT6A serves as a matchmaker introducing chemokines to tumor-associated macrophages in pancreatic ductal adenocarcinoma

Fig. 7

A Schematic diagram showing the tail vein injection of anti-CD47 nanobody into mice after subcutaneous injection of CCT6A-silenced or control KPC cells. (n = 6). Created with BioRender.com. B Tumor volume curve. (n = 6). Black: subcutaneous injection of control KPC cells and tail vein injection of saline (sh-NC + Saline), red: subcutaneous injection of control KPC cells and tail vein injection of anti-CD47 nanobody (sh-NC + anti-CD47), blue: subcutaneous injection of CCT6A-silenced KPC cells and tail vein injection of saline (sh-CCT6A + Saline), and green: subcutaneous injection of CCT6A-silenced KPC cells and tail vein injection of anti-CD47 nanobody (sh-CCT6A + anti-CD47). (n = 6). General images (C) and tumor weights (D) of subcutaneous tumors. (n = 6). E IHC analysis of CCT6A and tyramide signal amplification (TSA) -multiplex IF (mIF) staining (left) of F4/80 (green), CD163 (red) and iNOS (yellow) in the tumor sections. Scale bar, 20 μm. M2 (F4/80+CD163+) and M1 (F4/80+iNOS+) -positive cell count statistics (right) of the tumor sections. (n = 3). F Graphical abstract. Created with BioRender.com. Data presented as mean ± SD. n.s. no significant, *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001. One-way ANOVA analysis.

Back to article page